{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T04:25:44Z","timestamp":1648873544720},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Medical Sciences"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.advms.2014.01.005","type":"journal-article","created":{"date-parts":[[2014,6,9]],"date-time":"2014-06-09T21:31:41Z","timestamp":1402349501000},"page":"261-265","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: Results of a prospective single-centre study"],"prefix":"10.1016","volume":"59","author":[{"given":"Hanna","family":"Berak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Laskus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Ko\u0142akowska-Rz\u0105dzka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Wasilewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janusz J.","family":"Sta\u0144czak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Bardadin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo\u017cena","family":"Walewska-Zielecka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Horban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.advms.2014.01.005_bib0005","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1002\/hep.1840360715","article-title":"Introduction to therapy of hepatitis C","volume":"36","author":"Lindsay","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.advms.2014.01.005_bib0010","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/hep.510280430","article-title":"10-Year follow-up after interferon-alpha therapy for chronic hepatitis C","volume":"28","author":"Lau","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.advms.2014.01.005_bib0015","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1089-3261(02)00072-7","article-title":"Pegylated interferons","volume":"7","author":"Karnam","year":"2003","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.advms.2014.01.005_bib0020","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/00003088-200140070-00005","article-title":"Pegylation: a novel process for modifying pharmacokinetics","volume":"40","author":"Harris","year":"2001","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl. 1","key":"10.1016\/j.advms.2014.01.005_bib0025","first-page":"19","article-title":"Pegylation of interferon alfa: structural and pharmacokinetic properties","volume":"23","author":"Pedder","year":"2003","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.advms.2014.01.005_bib0030","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","article-title":"Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection","volume":"361","author":"McHutchison","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.advms.2014.01.005_bib0035","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1053\/j.gastro.2009.10.005","article-title":"Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection","volume":"138","author":"Ascione","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.advms.2014.01.005_bib0040","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/hep.23504","article-title":"Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials","volume":"51","author":"Awad","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.advms.2014.01.005_bib0045","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/0168-8278(95)80269-X","article-title":"The nomenclature of chronic hepatitis: time for a change","volume":"22","author":"Scheuer","year":"1995","journal-title":"J Hepatol"},{"key":"10.1016\/j.advms.2014.01.005_bib0050","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1053\/gast.2002.35950","article-title":"Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C","volume":"123","author":"McHutchison","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.advms.2014.01.005_bib0055","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1053\/gast.2001.21212","article-title":"Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection","volume":"120","author":"Bain","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.advms.2014.01.005_bib0060","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1086\/315283","article-title":"Virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes\/macrophages and lymphocytes","volume":"181","author":"Laskus","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.advms.2014.01.005_bib0065","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1365-2249.1996.tb08296.x","article-title":"Detection of hepatitis C virus (HCV) proteins by immunofluorescence and HCV RNA genomic sequences by non-isotopic in situ hybridization in bone marrow and peripheral blood mononuclear cells of chronically HCV-infected patients","volume":"103","author":"Sansonno","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.advms.2014.01.005_bib0070","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/hep.20087","article-title":"Frequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes","volume":"39","author":"Ducoulombier","year":"2004","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.advms.2014.01.005_bib0075","doi-asserted-by":"crossref","first-page":"370","DOI":"10.2478\/v10039-012-0024-8","article-title":"Variability of hepatitis C virus hypervariable region 1 (HVR-1) during the early phase of pegylated interferon and ribavirin therapy","volume":"57","author":"Caraballo Cort\u00e9s","year":"2012","journal-title":"Adv Med Sci"},{"key":"10.1016\/j.advms.2014.01.005_bib0080","first-page":"330A","article-title":"Long-lasting sustained virological response in chronic hepatitis C patients previously treated with 40kD peginterferon alpha-2A (Pegasys)","volume":"34","author":"Swain","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.advms.2014.01.005_bib0085","first-page":"244A","article-title":"Durability of sustained virologic response in patients with chronic hepatitis C after treatment with interferon alpha-2B alone or in combination with ribavirin","volume":"34","author":"McHutchison","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.advms.2014.01.005_bib0090","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0168-8278(99)80129-9","article-title":"Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon","volume":"30","author":"Reichard","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.advms.2014.01.005_bib0095","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/hep.22319","article-title":"Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial","volume":"47","author":"Yu","year":"2008","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.advms.2014.01.005_bib0100","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2478\/v10039-011-0056-5","article-title":"Risk score based PEG interferon alpha 2b and ribavirin treatment response estimation model for genotype 1 chronic hepatitis C patients","volume":"56","author":"Jurczyk","year":"2011","journal-title":"Adv Med Sci"},{"issue":"February (2)","key":"10.1016\/j.advms.2014.01.005_bib0105","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/qjmed\/hcs214","article-title":"Direct-acting antiviral therapies for hepatitis C. genotype 1 infection: a multiple treatment comparison meta-analysis","volume":"106","author":"Cooper","year":"2013","journal-title":"QJM"},{"issue":"September (3)","key":"10.1016\/j.advms.2014.01.005_bib0110","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jhep.2013.04.035","article-title":"Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) \u2013 NCT01514890","volume":"59","author":"H\u00e9zode","year":"2013","journal-title":"J Hepatol"}],"container-title":["Advances in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S189611261400042X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S189611261400042X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T14:21:04Z","timestamp":1538576464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S189611261400042X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S189611261400042X"],"URL":"https:\/\/doi.org\/10.1016\/j.advms.2014.01.005","relation":{},"ISSN":["1896-1126"],"issn-type":[{"value":"1896-1126","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: Results of a prospective single-centre study","name":"articletitle","label":"Article Title"},{"value":"Advances in Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.advms.2014.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Medical University of Bialystok. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.","name":"copyright","label":"Copyright"}]}}